Abstract:Objective To evaluate the efficacy and safety of common therapy and individualized treatment in newly diagnosed patients with Helicobacter pylori (H.pylori) infection.Methods From March 2008 to February 2010,September 2013 to April 2014,January to October 2015,a total of 1 440 patients with H.pylori infection who received eradication therapy and with complete clinical data were retrospectively enrolled.Each was 350 cases in individualized treatment group,clarithromycin and bismuth containing quadruple therapy group and concomitant therapy group.A total of 100 cases were in standard triple therapy group,90 cases in sequential therapy group,and 200 cases in levofloxacin and bismuth-containing quadruple therapy group.The eradication rate of H.pylori,incidence of adverse events and compliance rate were compared in the six groups.Chi square test was performed for statistical analysis.Results The results of intention-to-treat analysis indicated that there was no statistically significant difference in H.pylori eradication rates among six groups (x2 =0.985,P=0.323).However,the results of modified intention-to-treat analysis showed that H.pylori eradication rate of individualized treatment group was the highest (92.5％ (282/305) and 93.3％ (278/298)),second was levofloxacin and bismuth-containing quadruple therapy group (90.3％ (167/185) and 91.6％ (164/179)),and the differences were statistically significant (x2 =11.285 and 13.981,both P＜0.01).There was statistically significant difference in indcidence of adverse events among the six groups (x2 =5.692,P=0.018),the incidence of adverse events in levofloxacin and bimuth-containing quadruple therapy group was lowest (16.2 ％ (30/185)),and second was individualized treatment group (21.0％ (64/305)).There was statistically significant difference in compliance rates among the six groups (x2 =4.712,P=0.023),the compliance rates of standard triple therapy group and sequential therapy group were highest (100％ (100/100) and 100％ (90/90)),and second was individualized treatment group (97.7％ (298/305)).Conclusions Both the levofloxacin and bimuth-containing quadruple therapy group and individualized treatment group can effectively eradicate H.pylori infection.The former may be safe and effective to patients unable to receive individualized therapy.

Telephone-Based Reeducation of Drug Administration for Helicobacterpylori Eradication: A Multicenter Randomized Controlled Study

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Current Status of Helicobacter Pylori Eradication and Risk Factors for Eradication Failure

Short-term Outcomes and Intermediate-Term Follow-Up of Helicobacter Pylori Infection Treatment for Naïve Patients: a Retrospective Observational Study.

Application of a semi-automatic, intensive follow-up for improving efficacy and adherence of <i>Helicobacter pylori</i> eradication therapy: A randomized controlled trial

Is Tailored Therapy Based on Antibiotic Susceptibility Effective ? a Multicenter, Open-Label, Randomized Trial

Outcomes of Furazolidone- and Amoxicillin-Based Quadruple Therapy for Helicobacter Pylori Infection and Predictors of Failed Eradication.

Application of a WeChat-based mini-app as a patient reminder in Helicobacter pylori eradication: a prospective multi-center randomized controlled study

Is Short-Term Therapy Really Sufficient to Eradicate Helicobacter Pylori Infection?

Non-bismuth Quadruple Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication: a Randomized Controlled Study

Effect of 10-day Sequential Therapy Combined with Health Education on Patients with Helicobacter Pylori Eradica-tion Therapy Failure

Eradication Treatment of Helicobacter pylori Infection Based on Molecular Pathologic Antibiotic Resistance

Eradication Of H Pylori Infection In A Rural Population: One-Day Quadruple Therapy Versus 7-Day Triple Therapy

High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study

Application of Endoscopy-based Tailored Therapy in the Eradication of Helicobacter pylori

Eradication Efficacy of Sequential Therapy Versus Standard Quadruple Therapy As Rescue Therapies for Failure of Helicobacter Pylori Eradication

Helicobacter pylori eradication with ecabet sodium, omeprazole, amoxicillin, and clarithromycin versus bismuth, omeprazole, amoxicillin, and clarithromycin quadruple therapy: a randomized, open-label, phase IV trial.

Real-World Situation of Eradication Regimens and Risk Factors for Helicobacter pylori Treatment in China: A Retrospective Single-Center Study

Comparative Study on Eradication Therapy of 1 440 Newly Diagnosed Patients with Helicobacter Pylori Infection

[Minocycline Quadruple Versus Tailored Therapy in Retreatment of Helicobacter Pylori Infection].

A Clinical Study of Proton Pump Inhibitor-containing Quadruple Regimen as First-line Therapy for Helicobacter pylori Eradication